| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00108-015-3806-9 |
| P698 | PubMed publication ID | 26782281 |
| P50 | author | Mario Schiffer | Q37370948 |
| P2093 | author name string | J Gottlieb | |
| H Suhling | |||
| R Taubert | |||
| C Bara | |||
| E Jäckel | |||
| J H Bräsen | |||
| P2860 | cites work | Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients | Q24683927 |
| Conventional vs. tablet computer-based patient education following lung transplantation--a randomized controlled trial | Q27317020 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial | Q33584895 | ||
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | Q33968031 | ||
| Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. | Q34181871 | ||
| Fibrosis with inflammation at one year predicts transplant functional decline. | Q34457101 | ||
| Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria | Q34565524 | ||
| Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection | Q34728157 | ||
| Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection | Q35085494 | ||
| Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data | Q35127106 | ||
| Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. | Q53591741 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center | Q62617628 | ||
| Histopathology of graft coronary disease | Q68192618 | ||
| Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management | Q71873465 | ||
| Morphologic criteria of chronic renal allograft rejection | Q74617360 | ||
| [Modified endothelial cells in graft vasculopathy] | Q77593031 | ||
| Long-term health-related quality of life after lung transplantation: different predictors for different dimensions | Q79675030 | ||
| Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation | Q80678156 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009 | Q84588508 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Natural killer cells play a critical role in cardiac allograft vasculopathy in an interleukin-6--dependent manner | Q85686911 | ||
| Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation | Q86932430 | ||
| De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients | Q35535173 | ||
| Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features | Q35546323 | ||
| Innate immunity and cardiac allograft rejection | Q35680596 | ||
| Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment | Q35742669 | ||
| Multiple facets of macrophages in renal injury | Q35836435 | ||
| Antibody-mediated organ-allograft rejection | Q36263023 | ||
| IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
| Liver biopsy interpretation for causes of late liver allograft dysfunction | Q36548482 | ||
| Acute and chronic rejection after lung transplantation | Q36638083 | ||
| Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 | ||
| Mechanisms of fibrogenesis | Q37068410 | ||
| T cell-mediated rejection of kidney transplants: a personal viewpoint. | Q37719749 | ||
| Antibody-mediated rejection in kidney transplantation: an update | Q37835834 | ||
| What is the long-term outcome of the liver allograft? | Q37856013 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| Impact of donor-specific antibodies on results of liver transplantation | Q38099545 | ||
| Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance | Q38120396 | ||
| Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies | Q38130585 | ||
| T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance | Q38461220 | ||
| Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. | Q39716270 | ||
| Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. | Q40477268 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited | Q43116382 | ||
| Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection | Q43747982 | ||
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
| The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy | Q44378940 | ||
| Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients | Q44437112 | ||
| Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy | Q44438446 | ||
| Cardiac-allograft vasculopathy | Q44566067 | ||
| Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. | Q44793703 | ||
| Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression | Q44899020 | ||
| The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. | Q45110783 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. | Q45385330 | ||
| Early and late humoral rejection: a clinicopathologic entity in two times | Q46245989 | ||
| Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation | Q46809816 | ||
| Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. | Q52924045 | ||
| Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. | Q53244973 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 25-37 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Die Innere Medizin | Q1194574 |
| P1476 | title | Chronic rejection: Differences and similarities in various solid organ transplants | |
| P478 | volume | 57 |
Search more.